Article

High-dose radiation for PCa effective at 10 years, has few side effects

Salt Lake City--New research shows that men with clinically localized prostate cancer who are treated to high dose levels with three-dimensional conformal radiation therapy achieve long-term PSA relapse-free survival with minimal side effects.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Related Content
Radioligand therapy shows promising safety in patients with mCRPC
March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke
The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Novel drug delivery approach shows promise for UTI
March 12th 2025

Novel drug delivery approach shows promise for UTI

Hannah Clarke
The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome
March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke
"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.
Phase 3 trial launches ArteraAI Prostate Test for treatment selection
March 11th 2025

Phase 3 trial launches ArteraAI Prostate Test for treatment selection

Hannah Clarke
The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.
© 2025 MJH Life Sciences

All rights reserved.